The Law and Practice of Off-Label Prescribing and Physician Promotion

被引:20
作者
Syed, Shariful A. [1 ,2 ,3 ,4 ]
Dixson, Brigham A. [1 ,2 ,3 ,4 ]
Constantino, Eduardo [1 ,2 ,3 ,4 ]
Regan, Judith [1 ,2 ,3 ,4 ]
机构
[1] SUNY Stony Brook, Dept Psychiat & Behav Sci, Stony Brook, NY 11794 USA
[2] SUNY Stony Brook, Dept Psychiat & Behav Sci, Psychiat, Stony Brook, NY 11794 USA
[3] CW Bill Young VA Med Ctr, Bay Pines, FL USA
[4] North Pursell & Ramos PLC, Nashville, TN USA
关键词
misbranded; approved use; intended use; physician promotion; law; pharmaceutical; DRUG-USE;
D O I
10.29158/JAAPL.200049-20
中图分类号
D9 [法律]; DF [法律];
学科分类号
0301 ;
摘要
Prescription of medications for off-label indications is an increasingly common practice; recent events highlight such prescribing as one of the cornerstones of evolving clinical treatment. Clinicians are afforded substantial deference in prescribing practices and other treatments falling within the realm of the actual practice of medicine, including prescribing for off-label indications. Yet clinicians are not necessarily free to promote a medication for the same off-label indication they may have just prescribed for a patient. While trends in jurisprudence appear to be favoring clinicians' freedom to promote prescription medication for any use, in a majority of jurisdictions, the U.S. government can still bring considerable weight to bear on clinicians promoting off-label uses of prescription medications. We review the relevant laws and regulations pertaining to off-label prescription and promotion, as well as the possible legal consequences. The regulations pertaining to physician and pharmaceutical manufacturers regarding off-label drug use are complex. Suggestions are provided to help physicians better navigate the medical-legal landscape when prescribing or promoting medications for off-label use. Physician mindfulness to pertinent legal precedents will allow them to prescribe and promote medications with a higher level of critical reasoning to optimize care and reduce risk.
引用
收藏
页码:53 / 59
页数:7
相关论文
共 50 条
  • [11] Off-label Prescriptions in Public Psychiatric Hospital Practice
    Andreoli, Laura
    Gaudoneix, Muriel
    Beauverie, Patrick
    de Beaurepaire, Renaud
    THERAPIE, 2013, 68 (06): : 347 - 359
  • [12] Off-label prescribing for allergic diseases in pre-school children
    Morais-Almeida, M.
    Cabral, A. J.
    ALLERGOLOGIA ET IMMUNOPATHOLOGIA, 2014, 42 (04) : 342 - 347
  • [13] Off-label and unlicensed medication prescribing in Neonatal Intensive Care Unit: current practice in the Kosovo University Hospital
    Koshi, Blerina
    Grapci, Arlinda Daka
    Koliqi, Rozafa
    Raka, Denis
    Grapci, Luljeta
    Morina, Rina
    Crcarevska, Maja Simonoska
    Dodov, Marija Glavas
    Raichki, Renata Slaveska
    GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE, 2023, 182 (1-2) : 13 - 22
  • [14] Exploratory Findings of Prescribing Unlicensed and Off-Label Medicines Among Children and Neonates
    Shakeel, Sadia
    Iffat, Wajiha
    Nesar, Shagufta
    Zaidi, Hina
    Jamshed, Shazia
    INTEGRATED PHARMACY RESEARCH AND PRACTICE, 2020, 9 : 33 - 39
  • [15] Restrictions On Pharmaceutical Detailing Reduced Off-Label Prescribing Of Antidepressants And Antipsychotics In Children
    Larkin, Ian
    Ang, Desmond
    Avorn, Jerry
    Kesselheim, Aaron S.
    HEALTH AFFAIRS, 2014, 33 (06) : 1014 - 1023
  • [16] Clinical Setting Influences Off-Label and Unlicensed Prescribing in a Paediatric Teaching Hospital
    Czarniak, Petra
    Bint, Lewis
    Favie, Laurent
    Parsons, Richard
    Hughes, Jeff
    Sunderland, Bruce
    PLOS ONE, 2015, 10 (03):
  • [17] Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center
    Lim, Mir
    Shulman, David S.
    Roberts, Holly
    Li, Anran
    Clymer, Jessica
    Bona, Kira
    Al-Sayegh, Hasan
    Ma, Clement
    DuBois, Steven G.
    CANCER MEDICINE, 2020, 9 (18): : 6658 - 6666
  • [18] Off-label or Off-limits?
    Ritchey, Michael L.
    JOURNAL OF UROLOGY, 2013, 190 (01) : 8 - 9
  • [19] Off-Label Use vs Off-Label Marketing Part 2: Off-Label Marketing- Consequences for Patients, Clinicians, and Researchers
    Van Norman, Gail A.
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2023, 8 (03): : 359 - 370
  • [20] Controversies in off-label prescriptions in dermatology: the perspective of the patient, the physician, and the pharmaceutical companies
    Franca, Katlein
    Litewka, Sergio
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2019, 58 (07) : 788 - 794